title: Cell therapy of pain: Characterization of human fetal chromaffin cells at early adrenal medulla development.
abstract: Adult adrenal chromaffin cells are being utilized for therapeutic transplantation. With the prospect of using fetal chromaffin cells in pain therapy, we studied their phenotype, proliferative power, function, and growth in vitro and in situ in order to determine the optimal time for implantation. Between 7 and 10 gestational weeks (GW), we isolated, in vitro, two types of chromaffin cells with a noradrenergic phenotype akin to that observed, in situ. Among the adherent chromaffin cells first observed in vitro, only a few samples expressed met-enkephalin, whereas almost all the neurosphere-like colonies, which appeared later, expressed it. However, neither of the two types of populations expressed an adrenergic phenotype in line with that observed in situ. At the upper limits of the voluntary abortion period authorized in France, this phenotype (12 GW) and met-enkephalin expression (13 GW) were evidenced in situ. For the first time in man, we demonstrate the secretion of noradrenaline in vitro by the two populations of cells. Consistent with this result, we also noted dopamine beta hydroxylase (DbetaH) mRNA expression in vitro and in situ within this period. These observations on the expression of these biological factors indicate that 9-10 GW would be the best stage for sampling these cells for preclinical transplantation experiments.
authors.affiliation: Laboratory of Pain and Cell Therapy, 133 Route de Narbonne, 31062 Toulouse Cedex, France.
authors.forename: H
authors.initials: H
authors.lastname: Zhou
authors.forename: J
authors.initials: J
authors.lastname: Aziza
authors.forename: J C
authors.initials: JC
authors.lastname: Sol
authors.forename: M
authors.initials: M
authors.lastname: Courtade-Saïdi
authors.forename: S
authors.initials: S
authors.lastname: Chatelin
authors.forename: C
authors.initials: C
authors.lastname: Evra
authors.forename: O
authors.initials: O
authors.lastname: Parant
authors.forename: Y
authors.initials: Y
authors.lastname: Lazorthes
authors.forename: S
authors.initials: S
authors.lastname: Jozan
mesh_terms: D000313:Adrenal Medulla / Q000166:cytology* / Q000196:embryology*; D001973:Bromodeoxyuridine / Q000493:pharmacokinetics; D049109:Cell Proliferation; D002478:Cells, Cultured; D019439:Chromaffin Cells / Q000145:classification / Q000502:physiology* / Q000648:ultrastructure; D002864:Chromogranins / Q000378:metabolism; D004744:Enkephalin, Methionine / Q000378:metabolism; D005333:Fetus / Q000166:cytology*; D018507:Gene Expression Regulation, Developmental / Q000502:physiology*; D005865:Gestational Age; D005968:Glutamate Decarboxylase / Q000378:metabolism; D006801:Humans; D010641:Phenotype; D050918:Phosphatidylethanolamine N-Methyltransferase / Q000378:metabolism; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D018709:Statistics, Nonparametric; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism
chemical_list: D002864:Chromogranins; D018809:Proliferating Cell Nuclear Antigen; D012333:RNA, Messenger; D004744:Enkephalin, Methionine; D014446:Tyrosine 3-Monooxygenase; C494489:PEMT protein, human; D050918:Phosphatidylethanolamine N-Methyltransferase; D005968:Glutamate Decarboxylase; D001973:Bromodeoxyuridine